Volkan YILMAZ
(Clinic of Physical Medicine and Rehabilitation, Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital)
EBRU KARACA UMAY
(Clinic of Physical Medicine and Rehabilitation, Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital)
İbrahim GÜNDOĞDU
(Clinic of Physical Medicine and Rehabilitation, Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital)
Nihal TEZEL
(Clinic of Physical Medicine and Rehabilitation, Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital)
Yıl: 2018Cilt: 40Sayı: 4ISSN: 2149-2247 / 2149-2549Sayfa Aralığı: 194 - 199İngilizce

94 0
Treatment Outcomes of Postmenopausal Osteoporosis in Patients with Stable Hypothyroidism: A 5-Year Follow-up Retrospective Study
Objective: The aim of this study was to evaluate the effects of hypothyroidism on the treatment outcomes of the postmenopausal osteoporosis (PMOP) treatment. Materials and Methods: A total of 50 patients with hypothyroidism who were also diagnosed with PMOP according to the lumbar and femur neck bone mass density (BMD) evaluation with dual X-ray absorptiometry who did not receive any treatment for PMOP, including calcium and vitamin D, were included in the study. The control group consisted of 47 patients with PMOP but had no comorbidity. Demographic features including age, height, weight, occupation, the level of education, menarche and menopause age, clothing style, daily calcium intake, tobacco and/or alcohol consumption, daily physical activity level, personal (or maternal) history of fragility fracture, and duration of hypothyroidism were recorded. Biochemical parameters including the BMD scores, calcium, phosphate, alkaline phosphatase, parathormone, calcidiol, osteocalcine, urine calcium, phosphate levels, and creatinine clearance were also recorded. Patients were treated with bisphosphonate, calcium, and vitamin D, and same parameters were evaluated at the end of the first and fifth year. Results: The average age of all individuals was 58.25±8.89 years, and the average duration of hypothyroidism diagnosis was 4.00 years. The demographic features and biochemical parameters before the PMOP treatment were not different between the patient and the control groups (p>0.005). The BMD scores of both groups were significantly improved at the end of the first and fifth years of the treatment (p<0.005), but the variations of the scores were not different. Conclusion: Hypothyroidism with stable or unstable thyroid functions does not affect the PMOP treatment prognosis in Turkish population.
Fen > Tıp > Genel ve Dahili Tıp
DergiAraştırma MakalesiErişime Açık
  • Jang J, Kim Y, Shin J, Lee SA, Choi Y, Park EC. Association between thyroid hormones and metabolic syndrome. BMC Endocr Disord 2018; 18(1): 2-9. [CrossRef]
  • Kinne A, Schülein R, Krause G. Primary and secondary thyroid hormone transporters. Thyroid Res 2011; 3(4): 7. [CrossRef]
  • Nicholls JJ, Brassill NJ, Williams GR, Bassett JHD. The skeletal consequences of thyrotoxicosis. J Endocrinol 2012; 213: 209-21. [CrossRef]
  • Khan SH, Manzoor SM, Niazi NK, Asif N, Ijaz A, Fazal N. Association of metabolic risks with subclinical hypothyroidism: A cross sectional study. Pak J Med Sci 2018; 34: 357-62. [CrossRef]
  • Aoki Y, Belin RM, Clickner R, Jeffries R, Phillips L, Mahaffey KR. Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002). Thyroid 2007; 17(12):1211-23. [CrossRef]
  • Chang CH, Yeh YC, Caffrey JL, Chuang LM, Tu YK. Metabolic syndrome is associated with an increased incidence of subclinical Hypothyroidism. Sci Rep 2017; 7(1): 3-8. [CrossRef]
  • Tagami T, Kimura H, Ohtani S, Tanaka T, Hata S, Saito M, et al. Multi-center study on the prevalence of hypothyroidism in patients with hypercholesterolemia. Endocr J 2011; 58(6): 449-57. [CrossRef]
  • Razvi S, Weaver JU, Vanderpump MP, Pearce SH. The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. J Clin Endocrinol Metab 2010; 95(4):1734-40. [CrossRef]
  • Ahmed LA, Schirmer H, Berntsen GK, Fønnebø V, Joakimsen RM. Self-reported diseases and the risk of non-vertebral fractures: the Tromsø study. Osteoporos Int 2006; 17(1): 46-53. [CrossRef]
  • Kısakol G, Kaya A, Gonen S, Tunc R. Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism. Endocr J 2003; 50(6): 657-61. [CrossRef]
  • Marwaha RK, Garg MK, Tandon N, Kanwar R, Narang A, Sastry A, et al. Thyroid function and bone mineral density among Indian subjects. Indian J Endocrinol Metab 2012; 16(4): 575-9. [CrossRef]
  • González-Rodríguez LA1, Felici-Giovanini ME, Haddock L. Thyroid dysfunction in an adult female population: A population-based study of Latin American Vertebral Osteoporosis Study (LAVOS) - Puerto Rico site. P R Health Sci J 2013; 32(2): 57-62.
  • Kim BJ, Lee SH, Bae SJ, Kim HK, Choe JW, Kim HY, et al. The association between serum thyrotropin (TSH) levels and bone mineral density in healthy euthyroid men. Clin Endocrinol 2010; 73(3): 396403. [CrossRef]
  • Chawia J, Sharma N, Arora D, Arora M, Shukla L. Bone densitometry status and its associated Factors in peri and post menopausal females: A cross sectional study from a tertiary care centerin India. Taiwan J Obstet Gynecol 2018; 57(1): 100-5. [CrossRef]
  • Segna D, Bauer DC, Feller M, Schneider C, Fink HA, Aubert CA et al. Association between subclinical thyroid dysfunction and change in bone mineral density in prospective cohorts. J Intern Med 2018; 283(1): 56-72. [CrossRef]
  • Williams GR, Bassett JHD. Thyroid disease and bone health. J Endocrinol Invest 2018; 41(1): 99-109. [CrossRef]
  • Polovina SP, Miljic D, Zivojinovic S, Milic N, Micic D, Popovic Brkic V. The impact of thyroid autoimmunity (TPOAb) on bone density and fracture risk in postmenopausal women. Hormones (Athens) 2017; 16(1): 54-61.
  • Abrahamsen B, Jørgensen HL, Laulund AS, Nybo M, Bauer DC, Brix TH, et al. The excess risk of major osteoporotic fractures in hypothyroidism is driven by cumulative hyperthyroid as opposed to hypothyroid time: an observational register-based time-resolved cohort analysis. J Bone Miner Res 2015; 30(5): 898-905. [CrossRef]
  • Kyriakakis N, Lynch J, Ajjan R, Murray RD. The effects of pituitary and thyroid disorders on haemostasis: potential clinical implications. Clin Endocrinol (Oxf) 2016; 84(4): 473-84. [CrossRef]
  • Viniol A, Hickstein L, Walker J, Donner-Banzhoff N, Baum E, Becker A. Influence of thyroid hormone therapy on fracture rate: A claims data cohort study. Bone 2016; (86): 86-90. [CrossRef]
  • Ercolano M, Drnovsek M, Croome M, Moos M, Fuentes AM, Viale F, Feldt-Rasmussen U, et al. Negative correlation between bone mineral density and TSH receptor antibodies in long-term euthyroid postmenopausal women with treated Graves’ disease. Thyroid Res 2013; 6(1): 11. [CrossRef]
  • Vestergaard P, Weeke J, Hoeck H, Nielsen H, Rungby J, Rejnmark L, et al. Fractures in patients with primary idiopathic hypothyroidism. Thyroid 2000; 10(4): 335-40. [CrossRef]
  • Lee W, Oh K, Rhee E, Jung C, Kim S, Yun E, et al. Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women. Arch Med Res 2006; 37(4): 511-6. [CrossRef]

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.